> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Edwards Lifesciences Lifts 2026 Sales Growth Forecast To About 11.5% On 10.5% Third-Quarter Gain
- URL: https://www.bullished.co/edwards-lifesciences-lifts-2026-sales-growth-forecast-to-about-11-5-on-10-5-third-quarter-831d3fc0/
- Published: 2026-11-04T21:41:23.000Z
- Updated: 2026-11-04T21:41:23.000Z
- Description: The heart valve maker also raised its aortic, mitral-tricuspid and adjusted earnings outlooks after sales reached $1.72 billion.
- Author: Matteo Parrino
- Tags: Earnings, EW, Industry: Healthcare

Edwards Lifesciences, which makes heart valves and related devices for structural heart disease, raised its full-year sales growth forecast to about 11.5% from a prior range of 10% to 11%, [the company said](https://www.sec.gov/Archives/edgar/data/0001099800/000109980026000053/ex-991q32026.htm?ref=bullished.co) Wednesday as third-quarter sales rose 10.5% to $1.72 billion. CEO Bernard Zovighian said the quarter's growth "exceeded expectations."

## Mitral and tricuspid lead the growth

[Sales rose 11.2%](https://www.businesswire.com/news/home/20261104708591/en/Edwards-Lifesciences-Reports-Third-Quarter-Results?ref=bullished.co) in constant currency, which strips out currency swings. Transcatheter mitral and tricuspid therapies jumped 44.0% to $207 million, or 45.6% in constant currency, and the company said procedure volumes there kept growing in the double digits.

Aortic valve replacement, by far the biggest line, [grew 8.0% to $1.24 billion](https://www.businesswire.com/news/home/20261104708591/en/Edwards-Lifesciences-Reports-Third-Quarter-Results?ref=bullished.co), or 8.8% in constant currency. Surgical valve sales rose 2.5% to $264 million.

Zovighian said the 11.2% constant-currency growth was "strong" and gave the company "the confidence to raise our full-year outlook." Edwards said growth rates were similar in the U.S. and abroad, and that average selling prices were stable globally.

## Earnings: $0.80 adjusted, $0.53 reported

Adjusted earnings per share were $0.80, up 19% from a year earlier. Earnings per share under standard accounting were $0.53, after a $220.2 million charge for impairment of an in-process research and development asset and fixed assets acquired in an acquisition.

Adjusted gross margin was 78.7%, against 77.9% a year earlier. Edwards ended September with about $3.1 billion in cash and about $600 million of debt.

## Raised outlook and a $1.3 billion buyback pool

Edwards raised its aortic sales growth guidance to 9.0% to 9.5% from 8% to 9%. It lifted mitral and tricuspid sales guidance to $780 million to $790 million from $760 million to $780 million, and adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05.

For the fourth quarter, it projects sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69\. The company assumes growth will come mainly from rising procedure volumes and less from share gains.

The company has bought back about $700 million of stock through the third quarter and has about $1.3 billion left under its repurchase authorization. It also noted FDA approval in October of its PASCAL Precision system for tricuspid regurgitation.

Edwards was set to discuss the results on a conference call at 2:00 p.m. PT Wednesday.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Edwards Lifesciences Corp (EW)](https://www.sec.gov/Archives/edgar/data/0001099800/000109980026000053/ew-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex-991q32026.htm — Edwards Lifesciences Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001099800/000109980026000053/ex-991q32026.htm?ref=bullished.co) — SEC EDGAR
- [Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics](https://finance.yahoo.com/markets/stocks/articles/curious-edwards-lifesciences-ew-q3-121507765.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Edwards' Q3 Earnings on the Horizon: What's in the Cards?](https://finance.yahoo.com/healthcare/articles/edwards-q3-earnings-horizon-whats-131400210.html?ref=bullished.co) — Yahoo Finance
- [Edwards Lifesciences Reports Third Quarter Results](https://www.businesswire.com/news/home/20261104708591/en/Edwards-Lifesciences-Reports-Third-Quarter-Results?ref=bullished.co) — businesswire.com